Cancer drug data release set to power next wave of therapeutic discovery

Unique data comparing almost 1,000 cancer cell lines’ responses to 453 licensed and experimental drugs is now freely available to the worldwide research community

Cancer drug data release set to power next wave of therapeutic discovery

Genomics of Drug Sensitivity in Cancer database in numbers

This week (25 July) the Genomics of Drug Sensitivity in Cancer project ( has released the results of four years of intense research to power genetic research into cancer treatment worldwide. The new data set builds on the previous six years’ study, and practically doubles the volume of novel data available on the website – making it the largest public dataset of its kind in the world.

This new data release brings the amount of freely available, open-access data on the website to 453 cancer treatment compounds, 989 cancer cell lines, 494,973 genomic associations and 386,293 drug dose response curves. The previous study has already enabled discoveries that led to drug trials of PARP inhibitors in childhood bone cancer, directly contributed to drug development in pharma, and powered 70 research studies across the globe. The datasets are accessed by over 350 users each day and this is set to increase with the new data release. The project team hope that this enhanced resource will help to power new discoveries and therapeutic options for many years to come.

The Genomics of Drug Sensitivity in Cancer project is a pioneering public-private partnership funded by Wellcome. It combines samples of hospital patients’ cancer cell lines with licensed and experimental cancer drugs from a number of pharmaceutical companies, and applies in-depth observation and genetic analysis to identify how the underlying changes in a person’s DNA affects how they will respond to treatment. The ultimate goal is to identify biomarkers that could be used in the clinic to identify which drugs will work best to treat a patient’s cancer, based on the tumour’s genetic profile.

Working together, the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA) have investigated samples from 30 different adult and paediatric cancers. The tumour types include blood cancers and solid tumours, primary and metastatic, common and rare. The novel data offers a rich resource with opportunities for cancer scientists to discover more about how cancer cells work, how they respond to treatment, and generate new therapeutics and drug combinations.

Now part of the Cancer Dependency Map (Cancer DepMap) project, the vast dataset is available on the website.

“We are delighted that we have been able to create, and release, this valuable data to the global cancer research community. Our Genomics of Drug Sensitivity in Cancer database is the world’s largest repository for information on how a cancer’s underlying genomic landscape influences its response to cancer treatments. We hope it will provide new insights that will point to new ways to target, and treat individual tumours.”

Mathew Garnett, co-lead of the Genomics of Drug Sensitivity in Cancer project, and group leader at the Wellcome Sanger Institute

The team have further data releases planned for the near future.

Notes to Editors
Selected Websites
Cracking cancer with CRISPRSanger ScienceCracking cancer with CRISPR
How Sanger scientists are using genetic surgery to understand the blueprint of life

The weird and wonderful world of organoidsSanger ScienceThe weird and wonderful world of organoids
Mini organs grown in the lab are boosting cancer research and drug discovery.

Cancer: Rogue CellsVideoCancer: Rogue Cells
This animation describes how cancer grows within the body and how different factors can lead to cancer development.

Role of Cancer GenesVideoRole of Cancer Genes
This flash animation shows you how DNA mutations are involved in the development of cancer. 

Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0)7900 607793

Recent News

UK launches whole genome sequence alliance to map spread of coronavirus
The Wellcome Sanger Institute will collaborate with expert groups across the country to analyse the genetic code of COVID-19 samples circulating in the UK, providing public health agencies with a unique tool to combat the virus
Sanger Institute scientist wins 2021 Biochemical Society award
Roser Vento-Tormo awarded an Early Career Research Award
Sanger Institute and Wellcome Genome Campus temporarily closed to all but critical research
In response to the rapidly changing COVID-19 pandemic, the Sanger Institute and its neighbours on the Wellcome Genome Campus will close all but critical and essential operations from Friday 20 March.